The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting
- 358 Downloads
Lenvatinib (an inhibitor of vascular endothelial growth factor (GF) receptors 1–3, fibroblast GF receptors 1–4, platelet-derived GF receptor α, rearranged during transfection, and stem cell factor receptor) was non-inferior to sorafenib in a phase 3 (REFLECT) trial of advanced hepatocellular carcinoma. This study examined the efficacy and safety of lenvatinib in a real-world setting.
This was a retrospective, multicenter, observational study. Inclusion and exclusion criteria were based on the phase 3 trial, and participants were observed for at least 12 weeks. Therapeutic effect was determined using the modified Response Evaluation Criteria In Solid Tumors (m-RECIST) at the 8th week. Patients received oral lenvatinib 12 mg/day (body weight > 60 kg) or 8 mg/day (body weight < 60 kg). Dose interruptions followed by reductions for lenvatinib-related toxicities were permitted. Grades of adverse events (AEs) complied with the Common Terminology Criteria for Adverse Events version 4.0.
All 16 patients included in this study had prior treatment history, and a median 3.9 years had passed since the first treatment. Fatigue, hypertension, and proteinuria were the most frequent AEs, and were higher than Grade 2. AEs could be controlled by appropriate dose reduction, interruption, and symptomatic treatment according to the protocol. In the m-RECIST evaluation at the 8th week, 0, 6, 8, and 1 patients had achieved complete response, partial response, stable disease, and progressive disease, respectively. The objective response rate was 40%.
Lenvatinib treatment could be accomplished with safety and good response in a real-world setting.
KeywordsLenvatinib Hepatocellular carcinoma Clinical practice Efficacy
Compliance with ethical standards
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.
Informed consent was obtained from all patients for being included in the study. All relevant institutional review boards approved the study.
- 15.Child CG, Turcotte JG. Surgery and Portal Hypertension. The Liver and Portal Hypertension. Philadelphia: Saunders; 1964. 50–64.Google Scholar
- 18.Common Terminology Criteria for Adverse Events v4.0 (CTCAE) May 28, 2009 NIH Publication No. 03-5410. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50
- 19.Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Itobayashi E, Shimada N, et al. Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: multicenter analysis. Hepatol Res 2018. https://doi.org/10.1111/hepr (Epub 2018 Aug 24) Google Scholar